The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Cetuximab has clearly increased the therapeutic armamentarium for the treatment of patients with mCRC. Studies looking at clinical, biochemical, and molecular markers for increased activity have ...

In this particular case, we assume an association between PI and cetuximab treatment to be the most likely. This is extremely rare, with only 10 cases described in the literature to date.

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. Final analysis of ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Pfizer has shared positive results from a late-stage study of its Braftovi (encorafenib) combination in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...